What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward?
Author:
Affiliation:
1. Dept. of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
2. SpinCeutica Inc, Santa Fe, NM, USA
Publisher
Informa UK Limited
Subject
Drug Discovery
Link
https://www.tandfonline.com/doi/pdf/10.1080/17460441.2020.1673362
Reference10 articles.
1. NTM drug discovery: status, gaps and the way forward
2. Macrolide/Azalide Therapy for Nodular/Bronchiectatic Mycobacterium avium Complex Lung Disease
3. Risk Factors for Recurrence after Successful Treatment of Mycobacterium avium Complex Lung Disease
4. Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mavintramycin A is a promising antibiotic for treating Mycobacterium avium complex infectious disease;Antimicrobial Agents and Chemotherapy;2024-03-06
2. Treatment of non-tuberculosis mycobacteria skin infections;Frontiers in Pharmacology;2023-09-05
3. Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria;Theranostics;2022
4. Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections;Clinical Pharmacokinetics;2021-03-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3